Table 3 Univariate analysis of clinicopathological variables for PFS after lanreotide therapy
Variable | Hazard ratio (95% CI) | p value |
|---|---|---|
EGOG performance status (1 vs. 0) | 3.749 (1.084–12.965) | 0.037* |
Primary tumour site (pancreas vs. other) | 0.864 (0.0.356–2.097) | 0.746 |
NET WHO grade (2 and 3 vs. 1) | 1.833 (0.611–5.499) | 0.279 |
Presence of carcinoid symptoms (yes vs. no) | 0.616 (0.203–1.868) | 0.392 |
Previous surgery (yes vs. no) | 0.720 (0.290–1.789) | 0.480 |
Previous chemotherapy (yes vs. no) | 0.947 (0.217–4.133) | 0.942 |
Lanreotide dose (90 mg vs. 120 mg) | 2.030 (0.464–8.888) | 0.347 |
Hepatic tumour volume assessed by CT/MRI (> 25% vs. 0–25%) | 0.466 (0.170–1.275) | 0.137 |